Kamada (KMDA) Stock: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$8.31
0.11 (1.34%)
â˛
5d:
-4.7%
30d:
-1.07%
90d:
+10.95%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KMDA is fairly priced but lacks strong directional signals. At -0.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KMDA is fairly priced but lacks strong directional signals. At -0.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.90
Based on 12.4% avg growth
INTRINSIC VALUE TODAY
$9.25
10.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $8.31, which is considered fair relative to its 30-day fair value range of $8.16 to $8.69. The stock's valuation (Forward PE: 14.4) is in line with its historical norms (14.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.1% over the next few years. This pessimistic expectation contrasts with the company's recent 23.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, KMDA is in a uptrend. The price is currently testing key support at $8.17. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KMDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+62.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KMDA is in a uptrend. The price is currently testing key support at $8.17. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KMDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+62.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.16 -
$8.69
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.5% below Wall St target ($13.50)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.16 -
$8.69
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.17
Resistance Level
$8.96
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.41
Wall Street Target
$13.50
(+62.5%)
Revenue Growth (YoY)
22.7%
Earnings Growth (YoY)
23.1%
Profit Margin
11.6%
Valuation Discount vs History
-0.1% cheaper
PE vs Historical
14.4 vs 14.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.1%
(market-implied from PE analysis)
1-Year Target
$8.30
(0%)
2-Year Target
$8.29
(0%)
3-Year Target
$8.29
(0%)
3-Yr Target (if PE normalizes)
(PE: 14â15)
$8.34
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 20.8%)
$20.73
(+149%)
Base:
(SPY PE: 14.4, Growth: 20.8%)
$14.64
(+76%)
Bear:
(PE: 12.2, Growth: 20.8%)
$12.44
(+50%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 22.16 | Current EPS (TTM): $0.37
Bull Case
$14.06
(+69%)
Analyst growth 55.9%, PE expands to 24.4
Base Case
$12.78
(+54%)
Market implied 55.9%, PE stable at 22.2
Bear Case
$5.58
(-33%)
Severe decline -20.0%, PE contracts to 18.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.4 to 14.5
Stabilization Target:
$8.36
(+0.6%)
PE Expansion Potential:
+0.6%
Share & Embed Analysis
Last updated: October 04, 2026 1:37 AM ET
Data refreshes hourly during market hours. Next update: 2:37 AM
Data refreshes hourly during market hours. Next update: 2:37 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
